Dose Appropriateness, Efficacy, and Safety of Rivaroxaban and Apixaban in the Treatment of Cancer-related Venous Thromboembolism: A Retrospective Study at a Single Center

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Last Modified
  • February 26, 2019
Creator
  • Bui, Thanh
    • Affiliation: Eshelman School of Pharmacy
Abstract
  • Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE). While the guideline-recommended anticoagulant for the treatment of cancer-associated VTE is low-molecular-weight heparin (LMWH), direct oral anticoagulants (DOAC) such as rivaroxaban and apixaban are often prescribed for various reasons including patient preference, convenience, and cost. Furthermore, a recent randomized controlled trial of edoxaban in cancer-related VTE showed similar efficacy and safety compared to LMWH. The purpose of this study was to retrospectively assess the appropriateness of rivaroxaban and apixaban dose as well as rate of VTE recurrence and bleeding outcomes in patients with cancer-related VTE treatment.
Date of publication
Keyword
DOI
Resource type
Rights statement
  • In Copyright
Advisor
  • Rodgers, Jo Ellen
Degree
  • Doctor of Pharmacy
Honors level
  • Honors
Degree granting institution
  • University of North Carolina at Chapel Hill
Graduation year
  • 2018
Language
  • English

Relations

Parents:

This work has no parents.

Items

Thumbnail Title Date Uploaded Visibility Actions
file details 2018_Bui.pdf 2019-05-18 Public Download